Last updated: February 7, 2026
Overview
Corlopam (Fenoldopam mesylate) is a vasodilator indicated primarily for hypertensive crises. It acts as a dopamine D1 receptor agonist, producing vasodilation without significantly affecting heart rate, which makes it suitable for acute settings. The drug's market prospects depend on hypertensive crisis incidence, hospital adoption rates, and competitive landscape.
Market Fundamentals
- Indications & Usage: Coronary hypertensive emergencies, perioperative hypertension. The drug is administered intravenously, limiting outpatient opportunities.
- Market Size Estimates: The global hypertensive crisis management market was valued at approximately $2.3 billion in 2022, with an expected compound annual growth rate (CAGR) of 4.5% over five years [1].
- Pricing & Reimbursement: In the U.S., an average dose costs around $500. Reimbursement depends on hospital formularies and insurance policies, considering the drug's intravenous administration.
Competitive Landscape
- Key Competitors: Nitroprusside, Nicardipine, Ebrantil (Urapidil), with some off-label use of other vasodilators.
- Market Share: Corlopam has a niche position; however, its use is limited where other vasodilators or antihypertensive agents suffice. Its IV route confines use to hospital settings.
- Differentiators: Rapid onset (many minutes) and selectivity for D1 receptors contribute to its safety and efficacy profile, particularly avoiding tachycardia.
Regulatory & Commercial Status
- Approval & Registrations: Approved in the U.S. by the FDA, also marketed in some other countries.
- Sales Trends: No significant recent growth observed, partly due to generic competition and limited indication expansion.
- Pipeline & Development: No ongoing large-scale trials or new indications committed publicly.
Financial Metrics & Investment Outlook
- Generic Competition: Marketed as a generic or off-patent product, leading to pressure on pricing.
- Doctor and Hospital Adoption: Adoption is cautious, mainly in specialized intensive care units rather than broad hospital settings.
- Revenue Streams: Limited, mainly from acute care hospital sales.
Risks & Opportunities
- Risks: Price erosion due to generics, limited ability to expand indications, competition from other IV vasodilators.
- Opportunities: Potential for new formulations or delivery systems, combination use in hypertensive emergencies, increasing prevalence of hypertensive crises driven by aging populations.
Key Financial Indicators
| Indicator |
Details |
| Estimated Market Size |
$2.3 billion (globally, 2022) |
| Growth Rate |
4.5% CAGR (2023-2028) |
| Price per Dose |
~$500 (U.S. average) |
| Annual Sales Volume |
Variable, estimates suggest under $200 million in U.S. |
| Market Penetration |
Limited, primarily hospital-based |
Investment Summary
Corlopam's market is constrained by its intravenous route, limited indications, and the presence of established competitors. Its revenue potential remains moderate, with the main value drivers being hospital adoption and price optimization. Future valuation hinges on the company's ability to innovate, expand indications, or improve delivery methods.
Key Takeaways
- Corlopam operates in a niche market with limited growth potential due to route of administration and competition.
- The overall hypertensive crisis market is growing, but Corlopam's share remains under pressure from generics and alternative therapies.
- No current pipeline or significant near-term developments could boost sales.
- Investment should consider risks associated with patent expiry, pricing pressure, and market share erosion.
FAQs
- What factors could enhance Corlopam's market share? Adoption of new delivery systems, expansion into outpatient settings, or new indications could improve its standing.
- How does Corlopam compare to its main competitors? It offers rapid vasodilation with fewer cardiovascular side effects than alternatives like nitroprusside, but its IV-only route limits outpatient use.
- What are the primary regulatory considerations? Corlopam is FDA-approved; maintaining registration in key markets is essential for continued sales.
- What is the impact of generics on Corlopam? Generics place downward pressure on prices, reducing profit margins.
- Are there emerging markets for Corlopam? Some developing countries with hypertensive crisis management needs could present growth opportunities, contingent on regulatory approval and market entry strategies.
Sources
[1] MarketsandMarkets, "Hypertensive Crisis Management Market," 2022.
